Last updated: February 22, 2026
What is the drug represented by NDC 72865-0140?
NDC 72865-0140 is identified as Firdapse (amifampridine). It is approved by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). This drug is marketed primarily by Catalyst Pharmaceuticals.
Market Landscape
Indication and Patient Population
- Lambert-Eaton Myasthenic Syndrome (LEMS): A rare autoimmune disorder characterized by weakness in the voluntary muscles.
- Prevalence: Approximately 3-4 cases per million people [1]. Estimated patient base in the U.S. is around 1,700–2,300.
Competitive Landscape
- Current Treatment Options: Limited options include off-label use of drugs like 3,4-diaminopyridine (3,4-DAP), compounded formulations, and supportive therapies.
- Firdapse: First FDA-approved treatment specifically for LEMS, giving it a first-mover advantage.
Market Size Estimation
- Estimated U.S. Market: Based on prevalence and treatment rates, the addressable market could comprise roughly 2,000 to 3,000 patients.
- Pricing Impact: As the sole approved medication, pricing exerts significant influence on market penetration.
Pricing Data and Reimbursement
Current Wholesale Acquisition Cost (WAC)
- Firdapse (amifampridine): Listed at approximately $375 per 10 mg tablet [2].
- Average patient dose: 10-20 mg three times daily.
- Monthly cost estimate: Between $3,375 and $6,750 per patient.
Insurance Coverage and Reimbursement
- Medicare/Medicaid: Coverage varies; access may depend on prior authorization.
- Commercial plans: Generally provide coverage, but out-of-pocket costs depend on tier placement and patient co-pay policies.
- Patient Assistance: Catalyst Pharmaceuticals offers programs to mitigate high out-of-pocket expenses, influencing adherence and market size.
Price Projections
| Year |
Projected Price Range (Monthly per Patient) |
Assumptions |
Source/Notes |
| 2023 |
$3,375 – $6,750 |
Current WAC and dosing practice |
Based on existing pricing data [2] |
| 2024 |
$3,375 – $6,750 |
No significant price change |
Market conditions and manufacturing costs stable |
| 2025 |
$3,550 – $7,000 |
Potential price increases due to inflation |
Historical pricing adjustments [2] |
| 2026 |
$3,700 – $7,200 |
Slight upward adjustment; market consolidation |
Industry trend analysis |
Factors Influencing Future Pricing
- Regulatory Changes: Price regulation for orphan drugs could cap future pricing.
- Market Competition: Introduction of generics or alternative therapies could pressure prices downward.
- Supply Chain Costs: Changes in manufacturing costs may influence pricing adjustments.
- Market Penetration: Increasing adoption among diagnosed patients might stabilize per-unit pricing through volume.
Market Entry and Growth Potential
- The orphan drug designation limits competition but emphasizes the importance of patient access programs and pricing strategies.
- Patient advocacy groups and payer policies increasingly influence access and reimbursement.
- Although the patient population is small, high per-unit pricing sustains revenue.
Summary
Firdapse, with an estimated monthly cost range of $3,375 to $6,750, dominates the rare disease market for LEMS. Over the next five years, prices are projected to modestly increase, barring significant policy or market shifts. The market size remains limited but lucrative on a per-patient basis, driven by tight regulatory exclusivity and unmet medical needs.
Key Takeaways
- NDC 72865-0140 (Firdapse) is the only FDA-approved drug for LEMS, targeting a small, well-defined patient population.
- Current average monthly treatment costs are approximately $4,000 to $6,750.
- Market growth depends heavily on diagnosis rates, insurance coverage, and regulatory environment.
- Price increases are likely to remain modest, constrained by orphan drug pricing regulations and market dynamics.
- Competitive threats are limited; the main challenges relate to pricing, reimbursement, and market access.
FAQs
Q1: How many patients are estimated to use Firdapse in the U.S.?
Approximately 2,000 to 3,000 patients, based on disease prevalence data.
Q2: What is the main cost component of Firdapse treatment?
The medication itself, priced at roughly $375 per 10 mg tablet, with typical doses leading to monthly costs between $3,375 and $6,750.
Q3: Are there generic alternatives to Firdapse?
No; Firdapse holds orphan drug exclusivity, delaying generic entry until at least 2027.
Q4: How does insurance impact patient access to Firdapse?
Coverage varies by payer; copay programs and prior authorization can affect affordability.
Q5: What factors might influence future drug pricing?
Regulatory policies, competitive dynamics, supply chain costs, and market penetration.
References
[1] Sanders, D. B., et al. (2017). Diagnosis and management of Lambert-Eaton myasthenic syndrome. Neurology, 89(4), 366-373.
[2] Catalyst Pharmaceuticals. (2023). Firdapse Pricing and Support Programs. Retrieved from https://www.catalystpharm.com/our-products/firdapse
